Founded in Seattle, Nortis is dedicated to revolutionizing the field of biomedical research through its advanced in vitro systems. The company's core mission is to enhance the understanding of human diseases by providing innovative tools that surpass traditional 2D cultures and animal models. Nortis offers the ParVivo™ Platform, a plug-and-play organ-on-chip technology that accelerates pre-clinical drug development by providing early indications of organ toxicity. This automated system enables researchers to test compounds quickly and at scale, creating physiologically relevant tissue microenvironments.

Nortis has garnered attention from notable figures in the biomedical field and has attracted significant investment to support its groundbreaking work. The company’s ParVivo™ Platform has been recognized for its potential to transform pre-clinical testing, leading to more accurate predictions of drug safety and efficacy. Nortis' contributions have had a substantial impact on the pharmaceutical industry, offering a more reliable and ethical alternative to animal testing and advancing the overall understanding of disease mechanisms.